Allogeneic neural stem cells therapy(University of Cambridge)

N/A

Report date: 2025/04/17 17:12:54

Base Information

Drug NameAllogeneic neural stem cells therapy(University of Cambridge)
Drug Alias NameNeural stem/progenitor cells (NSCs)therapy(University of Cambridge)Allogenic hNSC therapy (University of Cambridge)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Neural stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Fetal stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalySwitzerland
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of CambridgeCasa Sollievo Della Sofferenza
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of CambridgeCasa Sollievo Della Sofferenza
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A